Midostaurin, sold under the brand name Rydapt, is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia, myelodysplastic syndrome and advanced systemic mastocytosis.Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients. Reference standards of Midostaurin API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
Midostaurin
Catalogue No.:PA 13 2180000
CAS :
Molecular Formula : C35H30N4O4
Molecular Weight : 570.65
3-Hydroxy Midostaurin
Catalogue No.:PA 13 2181000
Molecular Formula : C35H30N4O5
Molecular Weight : 586.65
O-Desmethyl Midostaurin
Catalogue No.:PA 13 2181001
Molecular Formula : C34H28N4O4
Molecular Weight : 556.62
(R)-3-Hydroxy Midostaurin
Catalogue No.:PA 13 2181002
N-((5R,6S,7S,9R)-6-Methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-17-oxa-4b,9a,15-triaza-5,9-methanodibenzo[b,h]cyclonona[jkl]cyclopenta[e]-as-indacen-7-yl)-N-methylbenzamide
Catalogue No.:PA 13 2181003
N-((5S,6R,7R,9S)-6-Methoxy-5-methyl-14,16-dioxo-6,7,8,9,15,16-hexahydro-5H,14H-17-oxa-4b,9a,15-triaza-5,9-methanodibenzo[b,h]cyclonona[jkl]cyclopenta[e]-as-indacen-7-yl)-N-methylbenzamide
Catalogue No.:PA 13 2181007
Molecular Formula : C35H28N4O5
Molecular Weight : 584.63
7-Hydroxystaurosporine
Catalogue No.:PA 13 2181008
Molecular Formula : C28H26N4O4
Molecular Weight : 482.54
Midostaurin-13C6
Catalogue No.:PA STI 089341
Molecular Formula : C2913C6H30N4O4
Molecular Weight : 576.6
3-Hydroxy Midostaurin-13C6
Catalogue No.:PA STI 089342
Molecular Formula : C2913C6H30N4O5
Molecular Weight : 592.6
O-Desmethyl Midostaurin-13C6
Catalogue No.:PA STI 089343
Molecular Formula : C2813C6H28N4O4
Molecular Weight : 562.58
N-((5S,6R,7R,9R,16S)-16-Hydroxy-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-17-oxa-4b,9a,15-triaza-5,9-methanodibenzo[b,h]cyclonona[jkl]cyclopenta[e]-as-indacen-7-yl)-N-methylbenzamide
Catalogue No.:PA 13 2181009
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....